Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD 0.1450
0.00 (0.00%)
At close: Feb 11, 2026
Sernova Biotherapeutics Employees
Sernova Biotherapeutics had 8 employees as of October 31, 2025. The number of employees decreased by 9 or -52.94% compared to the previous year.
Employees
8
Change
-9
Growth
-52.94%
Revenue / Employee
n/a
Profits / Employee
-1.97M CAD
Market Cap
49.17M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Oct 31, 2025 | 8 | -9 | -52.94% |
| Jul 31, 2025 | 13 | -4 | -23.53% |
| Apr 30, 2025 | 16 | - | - |
| Oct 31, 2024 | 17 | - | - |
Sernova Biotherapeutics News
- 4 months ago - Sernova converts $13.3M debt to equity ahead of clinical milestone - Seeking Alpha
- 4 months ago - Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang - Newsfile Corp
- 5 months ago - Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors - TheNewswire
- 5 months ago - Sernova Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investor Conference - TheNewswire
- 7 months ago - Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes - GlobeNewsWire
- 9 months ago - Sernova Appoints Jonathan Rigby as Interim Chair - GlobeNewsWire
- 9 months ago - Chair of Sernova Biotherapeutics Resigns - GlobeNewsWire
- 9 months ago - Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes - GlobeNewsWire